Saturday, December 21, 2024
12/21/2024
PROJECT SUMMARY Endolysosomal dysfunction is a convergent mechanism in many brain disorders. We are studying genetic con- ditions caused by mutations in the endosomal Na+/H+ Exchanger 6 (NHE6). Through our work with affected families in the International Christianson Syndrome and NHE6 Gene Network Study, we have found three phe- notypes associated with NHE6 mutations: 1) Christianson Syndrome (CS), a profound intellectual disability af- fecting males with loss-of-function mutations; 2) the Female-specific NHE6 Mutation Carrier Syndrome (FCS); and 3) Non-Syndromic ID/Autism (NS-ID/ASD) which occurs in males who carry putative hypomorphic muta- tions in NHE6. The objective of this R01 renewal proposal is to define pathogenic mechanisms that cause NHE6-related disease, as well as to develop mechanistic linkages to other related developmental and degen- erative disorders. We find a high degree of relevance to Lysosome Disorders, as well as, Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD). Our central hypothesis is that loss of NHE6 leads to abnormal endo- some-lysosome fusion, thereby causing: 1) cell-autonomous defects, such as aberrant retrograde axonal transport and lysosomal deficiency; and 2) cell non-autonomous pathology, such as toxic exosome release, and activation of disease-associated glial. Our research team is in an excellent position to study NHE6-related disease bench-to-bedside. We have unique resources, including: NHE6 mutant mice and human stem cells; as well as an NHE6-null rat that shows endogenous tauopathy. We also have a long-standing relationship with the family-led Christianson Syndrome Association, as we lead the natural history studies. There are four Aims: Aim 1 focuses on defining the molecular mechanism whereby loss of NHE6 leads to an endosome-lysosome fusion defect. In Aim 2, we define molecular mechanisms governing the emergence of disease-associated astrocytes and microglia in NHE6-mutant brains. The impact of this Aim, in part, involves the strong overlap of disease- associated glial states with AD/ADRD. In Aim 3, we will define the mechanism whereby putative hypomorphic NHE6 mutations in patients with NS-ID/ASD cause developmental delays and behavioral regressions. In this Aim, we will dissect biological mechanisms in developmental regression, which are common but have re- mained largely undefined. In Aim 4, we will focus on FCS, and define potential cell non-autonomous disease mechanisms in female NHE6 mutation carriers, including assessment of tau toxicity. In this Aim, through study of patient-derived iPSCs and the female carrier rat, we will contribute to knowledge of the understudied female carrier syndrome, and also to elucidating disease mechanisms related to X-chromosome inactivation in female brain. Overall, this research will define mechanisms in new genetic diseases in males and females, and will establish linkages with more common disorders, including AD/ADRD, potentially identifying new therapeutic targets. Additionally, our research uses a powerful integrated translational approach, bridging patient-oriented studies to experimental models, thereby contributing to robust research outcomes with high societal impact.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).